Effective and safe proton pump inhibitor therapy in acid-related diseases–a position paper addressing benefits and potential harms of acid suppression

C Scarpignato, L Gatta, A Zullo, C Blandizzi… - BMC medicine, 2016 - Springer
Background The introduction of proton pump inhibitors (PPIs) into clinical practice has
revolutionized the management of acid-related diseases. Studies in primary care and …

[HTML][HTML] Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified

G Bruno, P Zaccari, G Rocco, G Scalese… - World journal of …, 2019 - ncbi.nlm.nih.gov
Proton pump inhibitors (PPIs) are common medications within the practice of
gastroenterology. These drugs, which act through the irreversible inhibition of the …

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy …

M Valgimigli, H Bueno, RA Byrne, JP Collet… - European heart …, 2018 - academic.oup.com
Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Adverse effects of proton pump inhibitors—evidence and plausibility

R Fossmark, TC Martinsen, HL Waldum - International journal of …, 2019 - mdpi.com
Proton pump inhibitors (PPIs) have been increasingly used over the last decades and there
are concerns about overuse and the numerous reported side-effects. It is uncertain whether …

Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences

G Ortiz-Guerrero, D Amador-Muñoz… - Neural …, 2018 - Wiley Online Library
Alzheimer's disease (AD) is the most common type of dementia, mainly encompassing
cognitive decline in subjects aged≥ 65 years. Further, AD is characterized by selective …

Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis

Y Nassar, S Richter - Journal of bone metabolism, 2018 - synapse.koreamed.org
Background This study's objective was to evaluate the association between proton-pump
inhibitor (PPI) use and bone fracture incidence and bone mineral density (BMD) by meta …

Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: a systematic review and meta-analysis

ER de Santiago, CT Sanchez-Vegazo… - Endoscopy …, 2021 - thieme-connect.com
Background and study aims Antireflux mucosectomy (ARMS) and antireflux mucosal
ablation (ARMA) are new endoscopic procedures for patients with gastroesophageal reflux …

Adverse events of proton pump inhibitors: potential mechanisms

A Corsonello, F Lattanzio, S Bustacchini… - Current drug …, 2018 - ingentaconnect.com
Objective: We aimed at summarizing current evidence about mechanisms for potentially
harmful effects of Proton Pump Inhibitors (PPIs). Methods: A Pubmed search was performed …

[PDF][PDF] 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

M Valgimigli, H Bueno, RA Byrne… - Polish Heart …, 2017 - journals.viamedica.pl
Dokumenty przygotowane przez CPG nie zdejmują jednak w jakikolwiek sposób z
pracowników opieki zdrowotnej indywidualnej odpowiedzialności za podejmowanie …

Acid-suppressive therapy and risk of infections: pros and cons

L Fisher, A Fisher - Clinical drug investigation, 2017 - Springer
This narrative review summarises the benefits, risks and appropriate use of acid-
suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists …